Sirolimus- vs. paclitaxel-eluting stents in patients undergoing off-label percutaneous coronary intervention.
Studies of percutaneous coronary intervention (PCI) with drug-eluting stents in high-risk scenarios are often limited by short follow up and use definitions of "off-label" PCI which do not entirely mirror insert packages recommendations. We analyzed the incidence of cardiovascular events in 1050 consecutive patients undergoing off-label PCI with sirolimus- (n=581) or paclitaxel- (n=469) eluting stents. At 3 years, there were no differences between groups in terms of major cardiovascular events (adjusted hazard ratio 0.991; 95% CI, 0.758 to 1.295; p=0.945), despite slightly higher rates of myocardial infarction and late stent thrombosis seen among patients who received paclitaxel-eluting stents.
Ruperto
Cettina
C
Cardiology Department, Ferrarotto Hospital, University of Catania, Italy.
Capodanno
Davide
D
Cardiology Department, Ferrarotto Hospital, University of Catania, Italy; ETNA Foundation, Catania, Italy. Electronic address: dcapodanno@gmail.com.
Tamburino
Corrado
C
Cardiology Department, Ferrarotto Hospital, University of Catania, Italy; ETNA Foundation, Catania, Italy.
D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods / Q000592:standards; D054855:Drug-Eluting Stents / Q000592:standards; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D056687:Off-Label Use / Q000592:standards; D017239:Paclitaxel / Q000008:administration & dosage* / Q000592:standards; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage* / Q000592:standards
D017239:Paclitaxel; D020123:Sirolimus